-
2
-
-
0028176477
-
A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling
-
Carraway KL 3rd, Cantley LC. A neu acquaintance for erbB3 and erbB4: A role for receptor heterodimerization in growth signaling. Cell 78(1), 5-8 (1994
-
(1994)
Cell
, vol.78
, Issue.1
, pp. 5-8
-
-
Carraway III, K.L.1
Cantley, L.C.2
-
4
-
-
0031936410
-
Specificity within the EGF family/ErbB receptor family signaling network
-
Riese DJ 2nd, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 20(1), 41-48 (1998
-
(1998)
Bioessays
, vol.20
, Issue.1
, pp. 41-48
-
-
Riese II, D.J.1
Stern, D.F.2
-
5
-
-
0032860819
-
Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- And heterodimers
-
Muthuswamy SK, Gilman M, Brugge JS. Controlled dimerization of ErbB receptors provides evidence for differential signaling by homo- And heterodimers. Mol. Cell. Biol. 19(10), 6845-6857 (1999
-
(1999)
Mol. Cell. Biol.
, vol.19
, Issue.10
, pp. 6845-6857
-
-
Muthuswamy, S.K.1
Gilman, M.2
Brugge, J.S.3
-
6
-
-
0024822342
-
Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu
-
Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C. Epidermal growth factor receptors in breast cancer: Association with early relapse and death, poor response to hormones and interactions with neu. J. Steroid Biochem. 34(1-6):123-131 (1989
-
(1989)
J. Steroid Biochem.
, vol.34
, Issue.1-6
, pp. 123-131
-
-
Harris, A.L.1
Nicholson, S.2
Sainsbury, J.R.3
Farndon, J.4
Wright, C.5
-
7
-
-
37049183697
-
Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
-
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785), 177-182 (1987
-
(1987)
Science
, vol.235
, Issue.4785
, pp. 177-182
-
-
Slamon, D.J.1
Clark, G.M.2
Wong, S.G.3
Levin, W.J.4
Ullrich, A.5
McGuire, W.L.6
-
8
-
-
0026571910
-
The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients
-
Klijn JG, Berns PM, Schmitz PI, Foekens JA. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: A review on 5232 patients. Endocr. Rev. 13(1), 3-17 (1992
-
(1992)
Endocr. Rev.
, vol.13
, Issue.1
, pp. 3-17
-
-
Klijn, J.G.1
Berns, P.M.2
Schmitz, P.I.3
Foekens, J.A.4
-
9
-
-
0028330743
-
The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients
-
Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL. The epidermal growth factor receptor as a prognostic marker: Results of 370 patients and review of 3009 patients. Breast Cancer Res. Treat. 29(1), 41-49 (1994
-
(1994)
Breast Cancer Res. Treat.
, vol.29
, Issue.1
, pp. 41-49
-
-
Fox, S.B.1
Smith, K.2
Hollyer, J.3
Greenall, M.4
Hastrich, D.5
Harris, A.L.6
-
10
-
-
0028955388
-
Epidermal growth factor-related peptides and their receptors in human malignancies
-
Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19(3), 183-232 (1995
-
(1995)
Crit. Rev. Oncol. Hematol.
, vol.19
, Issue.3
, pp. 183-232
-
-
Salomon, D.S.1
Brandt, R.2
Ciardiello, F.3
Normanno, N.4
-
11
-
-
66249091930
-
The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine
-
Ross J, Slodkowska EA, Symmans WF et al. The HER-2 receptor and breast cancer: Ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14, 320-368 (2009
-
(2009)
Oncologist
, vol.14
, pp. 320-368
-
-
Ross, J.1
Slodkowska, E.A.2
Symmans, W.F.3
-
12
-
-
0032850677
-
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
-
Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17(9), 2639-2648 (1999
-
(1999)
J. Clin. Oncol.
, vol.17
, Issue.9
, pp. 2639-2648
-
-
Cobleigh, M.A.1
Vogel, C.L.2
Tripathy, D.3
-
13
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001
-
(2001)
N. Engl. J. Med.
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
-
14
-
-
79951974161
-
Randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study
-
Andersson M, Lidbrink E, Bjerre K et al. Randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. Am. Soc. Clin. Oncol. 29(3), 264-271 (2011
-
(2011)
Am. Soc. Clin. Oncol.
, vol.29
, Issue.3
, pp. 264-271
-
-
Andersson, M.1
Lidbrink, E.2
Bjerre, K.3
-
15
-
-
34548178720
-
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study
-
Burstein HJ, Keshaviah A, Baron AD et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 110(5), 965-972 (2007
-
(2007)
Cancer
, vol.110
, Issue.5
, pp. 965-972
-
-
Burstein, H.J.1
Keshaviah, A.2
Baron, A..D.3
-
16
-
-
73949105921
-
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized Phase III TAnDEM study
-
Kaufman B, Mackey JR, Clemens MR et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized Phase III TAnDEM study. J. Clin. Oncol. 27(33), 5529-5537 (2009
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.33
, pp. 5529-5537
-
-
Kaufman, B.1
Mackey, J.R.2
Clemens, M.R.3
-
17
-
-
33847147996
-
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers
-
Marcom PK, Isaacs C, Harris L et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res. Treat. 102(1), 43-49 (2007
-
(2007)
Breast Cancer Res. Treat.
, vol.102
, Issue.1
, pp. 43-49
-
-
Marcom, P.K.1
Isaacs, C.2
Harris, L.3
-
18
-
-
0036467826
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
-
Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3), 719-726 (2002
-
(2002)
J. Clin. Oncol.
, vol.20
, Issue.3
, pp. 719-726
-
-
Vogel, C.L.1
Cobleigh, M.A.2
Tripathy, D.3
-
19
-
-
2442645508
-
Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer
-
Burris H 3rd, Yardley D, Jones S et al. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J. Clin. Oncol. 22(9), 1621-1629 (2004
-
(2004)
J. Clin. Oncol.
, vol.22
, Issue.9
, pp. 1621-1629
-
-
Burris III, H.1
Yardley, D.2
Jones, S.3
-
20
-
-
11144357739
-
Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer
-
Sawaki M, Ito Y, Tada K et al. Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori 90(1), 40-43 (2004
-
(2004)
Tumori
, vol.90
, Issue.1
, pp. 40-43
-
-
Sawaki, M.1
Ito, Y.2
Tada, K.3
-
21
-
-
33646712747
-
Mechanisms of disease: Understanding resistance to HER2-Targeted therapy in human breast cancer
-
Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Mechanisms of disease: Understanding resistance to HER2-Targeted therapy in human breast cancer. Nat. Clin. Pract. Oncol. 3(5), 269-280 (2006
-
(2006)
Nat. Clin. Pract. Oncol.
, vol.3
, Issue.5
, pp. 269-280
-
-
Nahta, R.1
Yu, D.2
Hung, M.C.3
Hortobagyi, G.N.4
Esteva, F.J.5
-
22
-
-
3042676349
-
Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories
-
Gelmon KA, Mackey J, Verma S et al. Use of trastuzumab beyond disease progression: Observations from a retrospective review of case histories. Clin. Breast Cancer 5(1), 52-58
-
Clin. Breast Cancer
, vol.5
, Issue.1
, pp. 52-58
-
-
Gelmon, K.A.1
Mackey, J.2
Verma, S.3
-
23
-
-
84861041391
-
-
Discussion 59-62 (2004
-
(2004)
Discussion
, pp. 59-62
-
-
-
24
-
-
33645538673
-
Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study
-
Bartsch R, Wenzel C, Hussian D et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: An observational study. BMC Cancer 6, 63 (2006
-
(2006)
BMC Cancer
, vol.6
, pp. 63
-
-
Bartsch, R.1
Wenzel, C.2
Hussian, D.3
-
25
-
-
65349110371
-
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A german breast group 26/breast international group 03-05 study
-
Von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: A german breast group 26/breast international group 03-05 study. J. Clin. Oncol. 27(12), 1999-2006 (2009
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.12
, pp. 1999-2006
-
-
Von Minckwitz, G.1
Du Bois, A.2
Schmidt, M.3
-
26
-
-
39749097363
-
Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads
-
Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK. Trastuzumab-induced cardiotoxicity: Heart failure at the crossroads. Mayo Clin. Proc. 83(2), 197-203 (2008
-
(2008)
Mayo Clin. Proc.
, vol.83
, Issue.2
, pp. 197-203
-
-
Sengupta, P.P.1
Northfelt, D.W.2
Gentile, F.3
Zamorano, J.L.4
Khandheria, B.K.5
-
27
-
-
0037434791
-
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
-
Cho HS, Mason K, Ramyar KX et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421(6924), 756-760 (2003
-
(2003)
Nature
, vol.421
, Issue.6924
, pp. 756-760
-
-
Cho, H.S.1
Mason, K.2
Ramyar, K.X.3
-
28
-
-
20244378677
-
Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer
-
Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. 23(11), 2534-2543 (2005
-
(2005)
J. Clin. Oncol.
, vol.23
, Issue.11
, pp. 2534-2543
-
-
Agus, D.B.1
Gordon, M.S.2
Taylor, C.3
-
29
-
-
77949903478
-
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy
-
Baselga J, Gelmon KA, Verma S et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 28(7), 1138-1144 (2010
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.7
, pp. 1138-1144
-
-
Baselga, J.1
Gelmon, K.A.2
Verma, S.3
-
30
-
-
84862914692
-
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
-
Baselga J, Cortés J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012
-
(2012)
N. Engl. J. Med.
, vol.366
, Issue.2
, pp. 109-119
-
-
Baselga, J.1
Cortés, J.2
Kim, S.B.3
-
31
-
-
79952274439
-
Neoadjuvant pertuzumab and trastuzumab: Antitumor and safety analysis of a randomized Phase II Study ('NeoSphere')
-
Presented at: San Antonio, TX, USA, 8-12 December 2010
-
Gianni L, Pienkowski T, Im Y-H et al. Neoadjuvant pertuzumab and trastuzumab: Antitumor and safety analysis of a randomized Phase II Study ('NeoSphere'). Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010.
-
San Antonio Breast Cancer Symposium
-
-
Gianni, L.1
Pienkowski, T.2
Im, Y.-.H.3
-
32
-
-
84862894846
-
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2
-
doi:10.1200/JCO.37.4207 ( Epub ahead of print
-
Cortés J, Fumoleau P, Bianchi GV, Petrella TM. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: Activity and tolerability in patients with advanced human epidermal growth factor receptor 2. J. Clin. Oncol. doi:10.1200/JCO.37.4207 (2012) (Epub ahead of print
-
(2012)
J. Clin. Oncol.
-
-
Cortés, J.1
Fumoleau, P.2
Bianchi, G.V.3
Petrella, T.M.4
-
33
-
-
65349194552
-
A Phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC
-
Beeram M, Burris HA, Modi S et al. A Phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). J. Clin. Oncol. 26(Suppl.), 1028 (2008
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.SUPPL.
, pp. 1028
-
-
Beeram, M.1
Burris, H.A.2
Modi, S.3
-
34
-
-
70350623516
-
A Phase II study of trastuzumab-DM1 (T-DM1), a HER2, in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results
-
Vogel CL, Burris HA, Limentani S et al. A Phase II study of trastuzumab-DM1 (T-DM1), a HER2, in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results. J. Clin. Oncol. 27(Suppl. 15), 1079 (2009
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.SUPPL. 15
, pp. 1079
-
-
Vogel, C.L.1
Burris, H.A.2
Limentani, S.3
-
35
-
-
80054989315
-
Trastuzumab emtansine (T-DM1)*a novel agent for targeting HER2+ breast cancer
-
Burris HA 3rd, Tibbitts J, Holden SN, Sliwkowski MX, Lewis Phillips GD. Trastuzumab emtansine (T-DM1): A novel agent for targeting HER2+ breast cancer. Clin. Breast Cancer 11(5), 275-282 (2011
-
(2011)
Clin. Breast Cancer
, vol.11
, Issue.5
, pp. 275-282
-
-
Burris III, H.A.1
Tibbitts, J.2
Holden, S.N.3
Sliwkowski, M.X.4
Lewis Phillips, G..D.5
-
36
-
-
0028819660
-
Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
-
Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1(11), 1311-1318 (1995
-
(1995)
Clin. Cancer Res.
, vol.1
, Issue.11
, pp. 1311-1318
-
-
Goldstein, N.I.1
Prewett, M.2
Zuklys, K.3
Rockwell, P.4
Mendelsohn, J.5
-
37
-
-
33749011681
-
A Phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer
-
Modi S, D'Andrea G, Norton LP et al. A Phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin. Breast Cancer 7(3), 270-277 (2006
-
(2006)
Clin. Breast Cancer
, vol.7
, Issue.3
, pp. 270-277
-
-
Modi, S.1
D'Andrea, G.2
Norton, L.P.3
-
38
-
-
84861054477
-
The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized Phase II study (BALI-1
-
Presented at: Milan, Italy, 11 October 2010
-
Baselga J. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized Phase II study (BALI-1). Presented at: 35th ESMO Congress Presidential Symposium. Milan, Italy, 11 October 2010.
-
35th ESMO Congress Presidential Symposium
-
-
Baselga, J.1
-
39
-
-
0035884307
-
Targeting the epidermal growth factor receptor: A clinical reality
-
Baselga J. Targeting the epidermal growth factor receptor: A clinical reality. J. Clin. Oncol. 19(Suppl. 18), S41-S44 (2001
-
(2001)
J. Clin. Oncol.
, vol.19
, Issue.SUPPL. 18
-
-
Baselga, J.1
-
40
-
-
0037388251
-
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells
-
Anido J, Matar P, Albanell J et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 9(4), 1274-1283 (2003
-
(2003)
Clin. Cancer Res.
, vol.9
, Issue.4
, pp. 1274-1283
-
-
Anido, J.1
Matar, P.2
Albanell, J.3
-
41
-
-
2942592008
-
Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib
-
Burris HA 3rd. Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9(Suppl. 3), 10-15 (2004
-
(2004)
Oncologist
, vol.9
, Issue.SUPPL. 3
, pp. 10-15
-
-
Burris III, H.A.1
-
42
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006
-
(2006)
N. Engl. J. Med.
, vol.355
, Issue.26
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
-
43
-
-
63149110733
-
Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer
-
Lin NU, Diéras V, Paul D et al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15(4), 1452-1459 (2009
-
(2009)
Clin. Cancer Res.
, vol.15
, Issue.4
, pp. 1452-1459
-
-
Lin, N.U.1
Diéras, V.2
Paul, D.3
-
44
-
-
84855218212
-
LANDSCAPE: An FNCLCC Phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR
-
Bachelot D, Romieu G, Campone M et al. LANDSCAPE: An FNCLCC Phase II study with lapatinib (L) and capecitabine (C) in patients with brain metastases (BM) from HER2-positive (+) metastatic breast cancer (MBC) before whole-brain radiotherapy (WBR). J. Clin. Oncol. 29(Suppl.), 509 (2011
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 509
-
-
Bachelot, D.1
Romieu, G.2
Campone, M.3
-
45
-
-
54249153119
-
A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy
-
O'Shaughnessy J, Blackwell K, Burstein H et al. editors. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J. Clin. Oncol. 26(Suppl.), 1015 (2008
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.SUPPL.
, pp. 1015
-
-
O'Shaughnessy, J.1
Blackwell, K.2
Burstein, H.3
-
46
-
-
79952258750
-
First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer
-
Presented at: San Antonio, TX, USA, 8-12 December 2010
-
Baselga J, Bradbury I, Eidtmann H et al. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A Phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Presented at: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-12 December 2010.
-
San Antonio Breast Cancer Symposium
-
-
Baselga, J.1
Bradbury, I.2
Eidtmann, H.3
-
47
-
-
80051508992
-
TBCRC 006: A multicenter Phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer
-
Chang JCN, Mayer IA, Forero-Torres A et al. TBCRC 006: A multicenter Phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer. J. Clin. Oncol. 29(Suppl.) 505 (2011
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 505
-
-
Chang, J.C.N.1
Mayer, I.A.2
Forero-Torres, A.3
-
48
-
-
33846889291
-
Growth factor receptor interplay and resistance in cancer
-
Jones HE, Gee JM, Hutcheson IR, Knowlden JM, Barrow D, Nicholson RI. Growth factor receptor interplay and resistance in cancer. Endocr. Relat. Cancer 13(Suppl. 1), S45-S51 (2006
-
(2006)
Endocr. Relat. Cancer
, vol.13
, Issue.SUPPL. 1
-
-
Jones, H.E.1
Gee, J.M.2
Hutcheson, I.R.3
Knowlden, J.M.4
Barrow, D.5
Nicholson, R.I.6
-
49
-
-
9144251561
-
Nonendocrine pathways and endocrine resistance: Observations with antiestrogens and signal transduction inhibitors in combination
-
Nicholson RI, Hutcheson IR, Knowlden JM et al. Nonendocrine pathways and endocrine resistance: Observations with antiestrogens and signal transduction inhibitors in combination. Clin. Cancer Res. 10, 346s (2004
-
(2004)
Clin. Cancer Res.
, vol.10
-
-
Nicholson, R.I.1
Hutcheson, I.R.2
Knowlden, J.M.3
-
50
-
-
11244257032
-
The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- And estrogen-dependent gene expression in antiestrogen-resistant breast cancer
-
Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- And estrogen-dependent gene expression in antiestrogen-resistant breast cancer. Cancer Res. 65(1), 18-25 (2005
-
(2005)
Cancer Res.
, vol.65
, Issue.1
, pp. 18-25
-
-
Chu, I.1
Blackwell, K.2
Chen, S.3
Slingerland, J.4
-
51
-
-
73149115341
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
-
Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 27(33), 5538-5546 (2009
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.33
, pp. 5538-5546
-
-
Johnston, S.1
Pippen Jr., J.2
Pivot, X.3
-
52
-
-
69049101061
-
A randomized, Phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
-
Rixe O, Franco SX, Yardley DA et al. A randomized, Phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemother. Pharmacol. 64, 1139-1148 (2009
-
(2009)
Cancer Chemother. Pharmacol.
, vol.64
, pp. 1139-1148
-
-
Rixe, O.1
Franco, S.X.2
Yardley, D.A.3
-
53
-
-
13944262091
-
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity
-
Tsou HR, Overbeek-Klumpers EG, Hallett WA et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem. 48(4), 1107-1131 (2005
-
(2005)
J. Med. Chem.
, vol.48
, Issue.4
, pp. 1107-1131
-
-
Tsou, H.R.1
Overbeek-Klumpers, E.G.2
Hallett, W.A.3
-
54
-
-
77950497981
-
Neratinib, an Irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer
-
Burstein HJ, Sun Y, Dirix LY et al. Neratinib, an Irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28, 1301-1307 (2010
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 1301-1307
-
-
Burstein, H.J.1
Sun, Y.2
Dirix, L.Y.3
-
55
-
-
0033827119
-
Combinatorial chemoprevention of intestinal neoplasia
-
Torrance CJ, Jackson PE, Montgomery E et al. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 6(9), 1024-1028 (2000
-
(2000)
Nat. Med.
, vol.6
, Issue.9
, pp. 1024-1028
-
-
Torrance, C.J.1
Jackson, P.E.2
Montgomery, E.3
-
56
-
-
33744824672
-
Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors
-
Erlichman C, Hidalgo M, Boni JP et al. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J. Clin. Oncol. 24(15), 2252-2260 (2006
-
(2006)
J. Clin. Oncol.
, vol.24
, Issue.15
, pp. 2252-2260
-
-
Erlichman, C.1
Hidalgo, M.2
Boni, J.P.3
-
57
-
-
33847616363
-
Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer
-
Morris SR, Carey LA. Trastuzumab and beyond: New possibilities for the treatment of HER2-positive breast cancer. Oncology (Williston Park) 20(14), 1763-1771
-
Oncology (Williston Park
, vol.20
, Issue.14
, pp. 1763-1771
-
-
Morris, S.R.1
Carey, L.A.2
-
58
-
-
84861018238
-
-
discussion 71-72, 74-76 (2006
-
(2006)
Discussion
, vol.71-72
, pp. 74-76
-
-
-
59
-
-
49149117772
-
Results of the first Phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine
-
Holmes JP, Benavides LC, Gates JD et al. Results of the first Phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J. Clin. Oncol. 26(20), 3426-3433 (2008
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.20
, pp. 3426-3433
-
-
Holmes, J.P.1
Benavides, L.C.2
Gates, J..D.3
-
60
-
-
0141720783
-
Cancer vaccines: Between the idea and the reality
-
Finn OJ. Cancer vaccines: Between the idea and the reality. Nat. Rev. Immunol. 3(8), 630-641 (2003
-
(2003)
Nat. Rev. Immunol.
, vol.3
, Issue.8
, pp. 630-641
-
-
Finn, O.J.1
-
61
-
-
70350435441
-
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer
-
Disis ML, Wallace DR, Gooley TA et al. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J. Clin. Oncol. 27(28), 4685-4692 (2009
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.28
, pp. 4685-4692
-
-
Disis, M.L.1
Wallace, D.R.2
Gooley, T.A.3
-
62
-
-
80052206741
-
Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer
-
Miles D, Roche H, Martin M et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist 16, 1092-1100 (2011
-
(2011)
Oncologist
, vol.16
, pp. 1092-1100
-
-
Miles, D.1
Roche, H.2
Martin, M.3
-
63
-
-
36148976786
-
Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells
-
Neckers L, Kern A, Tsutsumi S. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells. Chem. Biol. 14(11), 1204-1206 (2007
-
(2007)
Chem. Biol.
, vol.14
, Issue.11
, pp. 1204-1206
-
-
Neckers, L.1
Kern, A.2
Tsutsumi, S.3
-
64
-
-
0035989680
-
HSP90 as a new therapeutic target for cancer therapy: The story unfolds
-
Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: The story unfolds. Expert Opin. Biol. Ther. 2(1), 3-24 (2002
-
(2002)
Expert Opin. Biol. Ther.
, vol.2
, Issue.1
, pp. 3-24
-
-
Maloney, A.1
Workman, P.2
-
65
-
-
1942431966
-
The achilles heel of ErbB-2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention
-
Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3(1), 51-60 (2004
-
(2004)
Cell Cycle
, vol.3
, Issue.1
, pp. 51-60
-
-
Citri, A.1
Kochupurakkal, B.S.2
Yarden, Y.3
-
66
-
-
12144266330
-
Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation
-
Citri A, Gan J, Mosesson Y, Vereb G, Szollosi J, Yarden Y. Hsp90 restrains ErbB-2/HER2 signalling by limiting heterodimer formation. EMBO J. 5(12), 1165-1170 (2004
-
(2004)
EMBO J.
, vol.5
, Issue.12
, pp. 1165-1170
-
-
Citri, A.1
Gan, J.2
Mosesson, Y.3
Vereb, G.4
Szollosi, J.5
Yarden, Y.6
-
67
-
-
0037075232
-
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2
-
Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21(8), 1159-1166 (2002
-
(2002)
Oncogene
, vol.21
, Issue.8
, pp. 1159-1166
-
-
Basso, A..D.1
Solit, D.B.2
Munster, P.N.3
Rosen, N.4
-
68
-
-
36849055007
-
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A Phase I dose-escalation study
-
Modi S, Stopeck AT, Gordon MS et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: A Phase I dose-escalation study. J. Clin. Oncol. 25(34), 5410-5417 (2007
-
(2007)
J. Clin. Oncol.
, vol.25
, Issue.34
, pp. 5410-5417
-
-
Modi, S.1
Stopeck, A.T.2
Gordon, M.S.3
-
69
-
-
79960985354
-
HSP90 inhibition is effective in breast cancer: A Phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
-
Modi S, Stopeck A, Linden H et al. HSP90 inhibition is effective in breast cancer: A Phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin. Cancer Res. 17(15), 1-8 (2011
-
(2011)
Clin. Cancer Res.
, vol.17
, Issue.15
, pp. 1-8
-
-
Modi, S.1
Stopeck, A.2
Linden, H.3
-
70
-
-
0034453098
-
The effects of insulin-like growth factors on tumorigenesis and neoplastic growth
-
Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr. Rev. 21(3), 215-244 (2000
-
(2000)
Endocr. Rev.
, vol.21
, Issue.3
, pp. 215-244
-
-
Khandwala, H.M.1
McCutcheon, I.E.2
Flyvbjerg, A.3
Friend, K.E.4
-
72
-
-
0032499440
-
Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
-
Hankinson SE, Willett WC, Colditz GA et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351(9113), 1393-1396 (1998
-
(1998)
Lancet
, vol.351
, Issue.9113
, pp. 1393-1396
-
-
Hankinson, S.E.1
Willett, W.C.2
Colditz, G.A.3
-
73
-
-
28244432561
-
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
-
Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65(23), 11118-11128 (2005
-
(2005)
Cancer Res.
, vol.65
, Issue.23
, pp. 11118-11128
-
-
Nahta, R.1
Yuan, L.X.2
Zhang, B.3
Kobayashi, R.4
Esteva, F.J.5
-
74
-
-
20144386856
-
Combination therapy enhances the inhibition of tumor growth with the fully human anti-Type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871
-
Cohen BD, Baker DA, Soderstrom C et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-Type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin. Cancer Res. 11(5), 2063-2073 (2005
-
(2005)
Clin. Cancer Res.
, vol.11
, Issue.5
, pp. 2063-2073
-
-
Cohen, B..D.1
Baker, D.A.2
Soderstrom, C.3
-
75
-
-
35148889523
-
A Phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor lgG1 monoclonal antibody, in patients with advanced solid tumors
-
Higano CS, Yu EY, Whiting SH et al. A Phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor lgG1 monoclonal antibody, in patients with advanced solid tumors. J. Clin. Oncol. (2007
-
(2007)
J. Clin. Oncol.
-
-
Higano, C.S.1
Yu, E.Y.2
Whiting, S.H.3
-
76
-
-
0034000338
-
Prognostic value of vascular endothelial growth factor in breast cancer
-
Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 5(Suppl. 1), 37-44 (2000
-
(2000)
Oncologist
, vol.5
, Issue.SUPPL. 1
, pp. 37-44
-
-
Gasparini, G.1
-
77
-
-
0025141337
-
What is the evidence that tumors are angiogenesis dependent?
-
Folkman J. What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst. 82(1), 4-6 (1990
-
(1990)
J. Natl Cancer Inst.
, vol.82
, Issue.1
, pp. 4-6
-
-
Folkman, J.1
-
78
-
-
0030576517
-
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
-
Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3), 353-364 (1996
-
(1996)
Cell
, vol.86
, Issue.3
, pp. 353-364
-
-
Hanahan, D.1
Folkman, J.2
-
79
-
-
0023157363
-
Angiogenic factors
-
Folkman J, Klagsbrun M. Angiogenic factors. Science 235(4787), 442-447 (1987
-
(1987)
Science
, vol.235
, Issue.4787
, pp. 442-447
-
-
Folkman, J.1
Klagsbrun, M.2
-
80
-
-
0028060380
-
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
-
Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265(5178), 1582-1584 (1994
-
(1994)
Science
, vol.265
, Issue.5178
, pp. 1582-1584
-
-
Dameron, K.M.1
Volpert, O.V.2
Tainsky, M.A.3
Bouck, N.4
-
81
-
-
0037699954
-
The biology of VEGF and its receptors
-
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med. 9(6), 669-676 (2003
-
(2003)
Nat. Med.
, vol.9
, Issue.6
, pp. 669-676
-
-
Ferrara, N.1
Gerber, H.P.2
LeCouter, J.3
-
82
-
-
0026708632
-
The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies
-
Kim KJ, Li B, Houck K, Winer J, Ferrara N. The vascular endothelial growth factor proteins: Identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 7(1), 53-64 (1992
-
(1992)
Growth Factors
, vol.7
, Issue.1
, pp. 53-64
-
-
Kim, K.J.1
Li, B.2
Houck, K.3
Winer, J.4
Ferrara, N.5
-
83
-
-
0035253739
-
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
-
Gordon MS, Margolin K, Talpaz M et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19(3), 843-850 (2001
-
(2001)
J. Clin. Oncol.
, vol.19
, Issue.3
, pp. 843-850
-
-
Gordon, M.S.1
Margolin, K.2
Talpaz, M.3
-
84
-
-
20044364346
-
Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
-
Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23(4), 792-799 (2005
-
(2005)
J. Clin. Oncol.
, vol.23
, Issue.4
, pp. 792-799
-
-
Miller, K..D.1
Chap, L.I.2
Holmes, F.A.3
-
85
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357(26), 2666-2676 (2007
-
(2007)
N. Engl. J. Med.
, vol.357
, Issue.26
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
86
-
-
54249120945
-
Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO
-
Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J. Clin. Oncol. 20(Suppl.) LBA1011 (2008
-
(2008)
J. Clin. Oncol.
, vol.20
, Issue.SUPPL.
-
-
Miles, D.1
Chan, A.2
Romieu, G.3
-
87
-
-
79953874259
-
RIBBON-1: Randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer
-
Robert NJ, Diéras V, Glaspy J, O'Shaughnessy J. RIBBON-1: Randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J. Clin. Oncol. 29, 1252-1260 (2011
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 1252-1260
-
-
Robert, N.J.1
Diéras, V.2
Glaspy, J.3
O'Shaughnessy, J.4
-
88
-
-
76949108277
-
RIBBON-2: A randomized, double-blind, placebo-controlled, Phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer
-
Presented at: San Antonio, TX, USA 10-13 December
-
Brufsky A, Bondarenko I, Smirnov V et al. RIBBON-2: A randomized, double-blind, placebo-controlled, Phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of HER2-negative metastatic breast cancer. Presented at: 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium. San Antonio, TX, USA 10-13 December 2009.
-
(2009)
32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium
-
-
Brufsky, A.1
Bondarenko, I.2
Smirnov, V.3
-
89
-
-
84855168056
-
Bevacizumab treatment for advanced breast cancer
-
Alvarez RH, Guarneri V, Icli F et al. Bevacizumab treatment for advanced breast cancer. Oncologist 16(12), 1684-1697 (2011
-
(2011)
Oncologist
, vol.16
, Issue.12
, pp. 1684-1697
-
-
Alvarez, R.H.1
Guarneri, V.2
Icli, F.3
-
90
-
-
0032972944
-
Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
-
Perrotte P, Matsumoto T, Inoue K et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res. 5(2), 257-265 (1999
-
(1999)
Clin. Cancer Res.
, vol.5
, Issue.2
, pp. 257-265
-
-
Perrotte, P.1
Matsumoto, T.2
Inoue, K.3
-
91
-
-
0036847719
-
Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-Antisense therapy
-
Li M, Ye C, Feng C et al. Enhanced antiangiogenic therapy of squamous cell carcinoma by combined endostatin and epidermal growth factor receptor-Antisense therapy. Clin. Cancer Res. 8(11), 3570-3578 (2002
-
(2002)
Clin. Cancer Res.
, vol.8
, Issue.11
, pp. 3570-3578
-
-
Li, M.1
Ye, C.2
Feng, C.3
-
92
-
-
59449097074
-
A Phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer
-
Dickler MN, Rugo HS, Eberle CA et al. A Phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin. Cancer Res. 14(23), 7878-7883 (2008
-
(2008)
Clin. Cancer Res.
, vol.14
, Issue.23
, pp. 7878-7883
-
-
Dickler, M.N.1
Rugo, H.S.2
Eberle, C.A.3
-
93
-
-
84856291930
-
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
-
Von Minckwitz G, Eidtmann H, Rezai M et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N. Engl. J. Med. 366, 299-309 (2012
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 299-309
-
-
Von Minckwitz, G.1
Eidtmann, H.2
Rezai, M.3
-
94
-
-
84856253589
-
Bevacizumab added to neoadjuvant chemotherapy for breast cancer NSABP B-40
-
Bear HD, Tang G, Rastogi P et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer NSABP B-40. N. Engl. J. Med. 366, 310-320 (2012
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 310-320
-
-
Bear, H..D.1
Tang, G.2
Rastogi, P.3
-
95
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9(1), 327-337 (2003
-
(2003)
Clin. Cancer Res.
, vol.9
, Issue.1
, pp. 327-337
-
-
Mendel, D.B.1
Laird, A..D.2
Xin, X.3
-
96
-
-
42949148257
-
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
-
Burstein HJ, Elias AD, Rugo HS et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 26(11), 1810-1816 (2008
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.11
, pp. 1810-1816
-
-
Burstein, H.J.1
Elias, A..D.2
Rugo, H.S.3
-
97
-
-
84860625265
-
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized Phase III study
-
Bergh J, Bondarenko IM, Lichinitser MR. First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: Results of a prospective, randomized Phase III study. J. Clin. Oncol. 30(9), 921-929 (2011
-
(2011)
J. Clin. Oncol.
, vol.30
, Issue.9
, pp. 921-929
-
-
Bergh, J.1
Bondarenko, I.M.2
Lichinitser, M.R.3
-
99
-
-
58149335533
-
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
-
Moreno-Aspitia A, Morton RF, Hillman DW et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J. Clin. Oncol. 27(1), 11-15 (2009
-
(2009)
J. Clin. Oncol.
, vol.27
, Issue.1
, pp. 11-15
-
-
Moreno-Aspitia, A.1
Morton, R.F.2
Hillman, D.W.3
-
100
-
-
84861086674
-
SOLTI-0701: A double-blind, randomized Phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared with placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC
-
Presented at: Berlin, Germany, 20-24 September
-
Baselga J, Segalla JGM, Roche H et al. editors. SOLTI-0701: A double-blind, randomized Phase 2b study evaluating the efficacy and safety of sorafenib (SOR) compared with placebo (PL) when administered in combination with capecitabine (CAP) in patients (pts) with locally advanced (adv) or metastatic (met) breast cancer (BC). Presented at: 34th ESMO Multidisciplinary Congress. Berlin, Germany, 20-24 September 2009.
-
(2009)
34th ESMO Multidisciplinary Congress
-
-
Baselga, J.1
Segalla, J.G.M.2
Roche, H.3
-
101
-
-
34948887693
-
ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein
-
Mi Y, Lou L. ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. Br. J. Cancer 97(7), 934-940 (2007
-
(2007)
Br. J. Cancer
, vol.97
, Issue.7
, pp. 934-940
-
-
Mi, Y.1
Lou, L.2
-
102
-
-
18244387980
-
A multicenter Phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer
-
Miller KD, Trigo JM, Wheeler C et al. A multicenter Phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res. 11(9), 3369-3376 (2005
-
(2005)
Clin. Cancer Res.
, vol.11
, Issue.9
, pp. 3369-3376
-
-
Miller, K..D.1
Trigo, J.M.2
Wheeler, C.3
-
103
-
-
84861040218
-
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: A double-blind,placebo-controlled, randomized Phase II study
-
Boér K, Láng I, Llombart-Cussac A et al. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: A double-blind,placebo-controlled, randomized Phase II study. Invest. New Drugs 30(2), 681-687 (2010
-
(2010)
Invest. New Drugs
, vol.30
, Issue.2
, pp. 681-687
-
-
Boér, K.1
Láng, I.2
Llombart-Cussac, A.3
-
104
-
-
0034655182
-
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration
-
Wood JM, Bold G, Buchdunger E et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 60(8), 2178-2189 (2000
-
(2000)
Cancer Res.
, vol.60
, Issue.8
, pp. 2178-2189
-
-
Wood, J.M.1
Bold, G.2
Buchdunger, E.3
-
105
-
-
0034282515
-
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model
-
Drevs J, Hofmann I, Hugenschmidt H et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. 60(17), 4819-4824 (2000
-
(2000)
Cancer Res.
, vol.60
, Issue.17
, pp. 4819-4824
-
-
Drevs, J.1
Hofmann, I.2
Hugenschmidt, H.3
-
106
-
-
77955748591
-
Biological evidence for dual antiangiogenic-Antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo
-
Banerjee S, A'Hern R, Detre S et al. Biological evidence for dual antiangiogenic-Antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. Clin. Cancer Res. (16), 4178-4187 (2010
-
(2010)
Clin. Cancer Res.
, vol.16
, pp. 4178-4187
-
-
Banerjee, S.1
A'Hern, R.2
Detre, S.3
-
107
-
-
79959286206
-
Randomized, placebo-controlled, double-blind, Phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer
-
Rugo HS, Stopeck AT, Joy AA et al. Randomized, placebo-controlled, double-blind, Phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J. Clin. Oncol. 29, 2459-2465 (2011
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 2459-2465
-
-
Rugo, H.S.1
Stopeck, A.T.2
Joy, A.A.3
-
108
-
-
84861050641
-
The anti-Tumor effect of motesanib in pre-clinical models of human basal-like breast cancer
-
Price JE, Alvarez RH, Xu C et al. The anti-Tumor effect of motesanib in pre-clinical models of human basal-like breast cancer. Cancer Res. 69(24), 5057 (2009
-
(2009)
Cancer Res.
, vol.69
, Issue.24
, pp. 5057
-
-
Price, J.E.1
Alvarez, R.H.2
Xu, C.3
-
109
-
-
79953196070
-
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A Phase 2, randomised, double-blind, placebo-controlled study
-
Martin M, Roche H, Pinte T et al. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A Phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol. 12, 369-376 (2011
-
(2011)
Lancet Oncol.
, vol.12
, pp. 369-376
-
-
Martin, M.1
Roche, H.2
Pinte, T.3
-
110
-
-
61749088975
-
HER2-Targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
-
Nielsen DL, Andersson M, Kamby C. HER2-Targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors. Cancer Treat Rev. 35(2), 121-136 (2009
-
(2009)
Cancer Treat Rev.
, vol.35
, Issue.2
, pp. 121-136
-
-
Nielsen, D.L.1
Andersson, M.2
Kamby, C.3
-
111
-
-
55249101007
-
Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer
-
Slamon D, Gomez HL, Kabbinavar F et al. editors. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. J. Clin. Oncol. 26(Suppl.) 1016 (2008
-
(2008)
J. Clin. Oncol.
, vol.26
, Issue.SUPPL.
, pp. 1016
-
-
Slamon, D.1
Gomez, H.L.2
Kabbinavar, F.3
-
112
-
-
77956842743
-
A Phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the princess margaret hospital Phase II consortium
-
Taylor S, Chia S, Dent S et al. A Phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: A trial of the princess margaret hospital Phase II consortium. Oncologist 15, 810-818 (2010
-
(2010)
Oncologist
, vol.15
, pp. 810-818
-
-
Taylor, S.1
Chia, S.2
Dent, S.3
-
113
-
-
3042581811
-
Farnesyl transferase inhibitors: The next targeted therapies for breast cancer?
-
O'Regan RM, Khuri FR. Farnesyl transferase inhibitors: The next targeted therapies for breast cancer? Endocr. Relat. Cancer 11(2), 191-205 (2004
-
(2004)
Endocr. Relat. Cancer
, vol.11
, Issue.2
, pp. 191-205
-
-
O'Regan, R.M.1
Khuri, F.R.2
-
114
-
-
0035132538
-
Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
-
End DW, Smets G, Todd AV et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61(1), 131-137 (2001
-
(2001)
Cancer Res.
, vol.61
, Issue.1
, pp. 131-137
-
-
End, D.W.1
Smets, G.2
Todd, A.V.3
-
115
-
-
18544412314
-
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer
-
Zujewski J, Horak ID, Bol CJ et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J. Clin. Oncol. 18(4), 927-941 (2000
-
(2000)
J. Clin. Oncol.
, vol.18
, Issue.4
, pp. 927-941
-
-
Zujewski, J.1
Horak, I..D.2
Bol, C.J.3
-
116
-
-
19944434195
-
A Phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer
-
Lebowitz PF, Eng-Wong J, Widemann BC et al. A Phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer. Clin. Cancer Res. 11(3), 1247-1252 (2005
-
(2005)
Clin. Cancer Res.
, vol.11
, Issue.3
, pp. 1247-1252
-
-
Lebowitz, P.F.1
Eng-Wong, J.2
Widemann, B.C.3
-
117
-
-
44849087679
-
A Phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy
-
Johnston SR, Semiglazov VF, Manikhas GM et al. A Phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res. Treat. 110(2), 327-335 (2008
-
(2008)
Breast Cancer Res. Treat.
, vol.110
, Issue.2
, pp. 327-335
-
-
Johnston, S.R.1
Semiglazov, V.F.2
Manikhas, G.M.3
-
118
-
-
33746015951
-
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: A Phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide
-
Sparano JA, Moulder S, Kazi A et al. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: A Phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. J. Clin. Oncol. 24(19), 3013-3018 (2006
-
(2006)
J. Clin. Oncol.
, vol.24
, Issue.19
, pp. 3013-3018
-
-
Sparano, J.A.1
Moulder, S.2
Kazi, A.3
-
119
-
-
32044466838
-
Exploiting the PI3K/AKT pathway for cancer drug discovery
-
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4(12), 988-1004 (2005
-
(2005)
Nat. Rev. Drug Discov.
, vol.4
, Issue.12
, pp. 988-1004
-
-
Hennessy, B.T.1
Smith, D.L.2
Ram, P.T.3
Lu, Y.4
Mills, G.B.5
-
120
-
-
0037205048
-
The phosphoinositide 3-kinase pathway
-
Cantley LC. The phosphoinositide 3-kinase pathway. Science 296(5573), 1655-1657 (2002
-
(2002)
Science
, vol.296
, Issue.5573
, pp. 1655-1657
-
-
Cantley, L.C.1
-
121
-
-
79955555659
-
Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer
-
Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist 16, 404-414 (2011
-
(2011)
Oncologist
, vol.16
, pp. 404-414
-
-
Hernandez-Aya, L.F.1
Gonzalez-Angulo, A.M.2
-
122
-
-
0032053709
-
Mechanisms and consequences of activation of protein kinase B/Akt
-
Downward J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr. Opin. Cell. Biol.10(2), 262-267 (1998
-
(1998)
Curr. Opin. Cell. Biol.
, vol.10
, Issue.2
, pp. 262-267
-
-
Downward, J.1
-
123
-
-
66849136781
-
Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
-
Baselga J, Semiglazov V, van Dam P et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 27, 2630-2637 (2009
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 2630-2637
-
-
Baselga, J.1
Semiglazov, V.2
Van Dam, P.3
-
124
-
-
35148885729
-
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
-
Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395-402 (2007
-
(2007)
Cancer Cell
, vol.12
, pp. 395-402
-
-
Berns, K.1
Horlings, H.M.2
Hennessy, B.T.3
-
125
-
-
78650984926
-
Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab
-
Andre F, Campone M, O'Regan R et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J. Clin. Oncol. 28, 5110-5115 (2010
-
(2010)
J. Clin. Oncol.
, vol.28
, pp. 5110-5115
-
-
Andre, F.1
Campone, M.2
O'Regan, R.3
-
126
-
-
80051751593
-
Phase I/II Study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy
-
Morrow PK, Wulf GM, Ensor J et al. Phase I/II Study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J. Clin. Oncol. 29, 3126-3132 (2011
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 3126-3132
-
-
Morrow, P.K.1
Wulf, G.M.2
Ensor, J.3
-
127
-
-
84863078767
-
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
-
Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520-529 (2012
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 520-529
-
-
Baselga, J.1
Campone, M.2
Piccart, M.3
Burris III, H.A.4
Rugo, H.S.5
-
128
-
-
0034790016
-
MTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
-
Yu K, Toral-Barza L, Discafani C et al. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8(3), 249-258 (2001
-
(2001)
Endocr. Relat. Cancer
, vol.8
, Issue.3
, pp. 249-258
-
-
Yu, K.1
Toral-Barza, L.2
Discafani, C.3
-
129
-
-
2942735384
-
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
-
Raymond E, Alexandre J, Faivre S et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22(12), 2336-2347 (2004
-
(2004)
J. Clin. Oncol.
, vol.22
, Issue.12
, pp. 2336-2347
-
-
Raymond, E.1
Alexandre, J.2
Faivre, S.3
-
130
-
-
23944439945
-
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
-
Chan S, Scheulen ME, Johnston S et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23(23), 5314-5322 (2005
-
(2005)
J. Clin. Oncol.
, vol.23
, Issue.23
, pp. 5314-5322
-
-
Chan, S.1
Scheulen, M.E.2
Johnston, S.3
-
131
-
-
8344231370
-
Phase II, 3-Arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: Preliminary results
-
Baselga J, Fumoleau P, Gil M et al. Phase II, 3-Arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: Preliminary results. J. Clin. Oncol. 22(Suppl. 14), 544 (2004
-
(2004)
J. Clin. Oncol.
, vol.22
, Issue.SUPPL. 14
, pp. 544
-
-
Baselga, J.1
Fumoleau, P.2
Gil, M.3
-
132
-
-
33748530840
-
Randomized 3-Arm, Phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer
-
Carpenter JT, Roche H, Campone M et al. Randomized 3-Arm, Phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23(Suppl. 16), 564 (2005
-
(2005)
J. Clin. Oncol.
, vol.23
, Issue.SUPPL. 16
, pp. 564
-
-
Carpenter, J.T.1
Roche, H.2
Campone, M.3
-
133
-
-
76049123027
-
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
-
Brachmanna SM, Hofmanna I, Schnella C, Fritsch C. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl Acad. Sci. USA 106(52) 22299-22304 (2009
-
(2009)
Proc. Natl Acad. Sci. USA
, vol.106
, Issue.52
, pp. 22299-22304
-
-
Brachmanna, S.M.1
Hofmanna, I.2
Schnella, C.3
Fritsch, C.4
-
134
-
-
73949128107
-
Histone deacetylase inhibitors in cancer therapy
-
Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27, 5459-5468 (2009
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 5459-5468
-
-
Lane, A.A.1
Chabner, B.A.2
-
135
-
-
79958084461
-
Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
-
Munster PN, Thurn KT, Thomas S et al. Phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br. J. Cancer 104(12), 1828-1835 (2011
-
(2011)
Br. J. Cancer
, vol.104
, Issue.12
, pp. 1828-1835
-
-
Munster, P.N.1
Thurn, K.T.2
Thomas, S.3
-
136
-
-
70249146546
-
Fibroblast growth factors in development and cancer: Insights from the mammary and prostate glands
-
Schwertfeger KL. Fibroblast growth factors in development and cancer: Insights from the mammary and prostate glands. Curr. Drug Target. 10, 632-644 (2009
-
(2009)
Curr. Drug Target.
, vol.10
, pp. 632-644
-
-
Schwertfeger, K.L.1
-
137
-
-
41149122199
-
Discovery of brivanib alaninate, a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215
-
Cai ZW, Zhang Y, Borzilleri RM et al. Discovery of brivanib alaninate, a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J. Med. Chem. 51, 1976-1980 (2008
-
(2008)
J. Med. Chem.
, vol.51
, pp. 1976-1980
-
-
Cai, Z.W.1
Zhang, Y.2
Borzilleri, R.M.3
-
138
-
-
79952116987
-
Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate
-
Shiang CY, Qi Y, Wang B et al. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res. Treat. 123(3), 747-755 (2010
-
(2010)
Breast Cancer Res. Treat.
, vol.123
, Issue.3
, pp. 747-755
-
-
Shiang, C.Y.1
Qi, Y.2
Wang, B.3
-
139
-
-
2942618768
-
A renaissance for SRC
-
Yeatman TJ. A renaissance for SRC. Nat. Rev. Cancer 4, 470-480 (2004
-
(2004)
Nat. Rev. Cancer
, vol.4
, pp. 470-480
-
-
Yeatman, T.J.1
-
140
-
-
33750076068
-
The role of Src in solid and hematologic malignancies
-
Alvarez RH, Kantarjian HM, Cortes JE. The role of Src in solid and hematologic malignancies. Cancer 107(8), 1918-1929 (2006
-
(2006)
Cancer
, vol.107
, Issue.8
, pp. 1918-1929
-
-
Alvarez, R.H.1
Kantarjian, H.M.2
Cortes, J.E.3
-
141
-
-
0020645860
-
Expression of pp60c-src protein kinase in adult and fetal human tissue: High activities in some sarcomas and mammary carcinomas
-
Jacobs C, Rubsamen H. Expression of pp60c-src protein kinase in adult and fetal human tissue: High activities in some sarcomas and mammary carcinomas. Cancer Res. 43, 1696-1702 (1983
-
(1983)
Cancer Res.
, vol.43
, pp. 1696-1702
-
-
Jacobs, C.1
Rubsamen, H.2
-
142
-
-
79953745096
-
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
-
Zhang S, Huang W-C, Li P et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 17(4), 461-469 (2011
-
(2011)
Nat. Med.
, vol.17
, Issue.4
, pp. 461-469
-
-
Zhang, S.1
Huang, W.-.C.2
Li, P.3
-
143
-
-
84857546448
-
Phase II study of single-Agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
-
Campone M, Bondarenko I, Brincat S et al. Phase II study of single-Agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann. Oncol. 23(3), 610-617 (2012
-
(2012)
Ann. Oncol.
, vol.23
, Issue.3
, pp. 610-617
-
-
Campone, M.1
Bondarenko, I.2
Brincat, S.3
-
144
-
-
0034641932
-
From bench to clinic with apoptosis-based therapeutic agents
-
Nicholson DW. From bench to clinic with apoptosis-based therapeutic agents. Nature 407(6805), 810-816 (2000
-
(2000)
Nature
, vol.407
, Issue.6805
, pp. 810-816
-
-
Nicholson, D.W.1
-
145
-
-
0032713075
-
Safety and antitumor activity of recombinant soluble Apo2 ligand
-
Ashkenazi A, Pai RC, Fong S et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104(2), 155-162 (1999
-
(1999)
J. Clin. Invest.
, vol.104
, Issue.2
, pp. 155-162
-
-
Ashkenazi, A.1
Pai, R.C.2
Fong, S.3
-
146
-
-
79251564088
-
A review of PARP inhibitors: From bench to bedside
-
Underhill C, Toulmonde M, Bonnefoi H. A review of PARP inhibitors: From bench to bedside. Ann. Oncol. 22, 268-279 (2011
-
(2011)
Ann. Oncol.
, vol.22
, pp. 268-279
-
-
Underhill, C.1
Toulmonde, M.2
Bonnefoi, H.3
-
147
-
-
77949686134
-
Final results of a randomized Phase II study demonstrating efficacy and safety of BSI-201, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC
-
O'Shaughnessy JOC, Pippen J, Patt D et al. Final results of a randomized Phase II study demonstrating efficacy and safety of BSI-201, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in metastatic triple negative breast cancer (TNBC). Cancer Res. 69(24), 3122 (2009
-
(2009)
Cancer Res.
, vol.69
, Issue.24
, pp. 3122
-
-
O'Shaughnessy, J.O.C.1
Pippen, J.2
Patt, D.3
-
148
-
-
78751610848
-
Iniparib plus chemotherapy in metastatic triple-negative breast cancer
-
O'Shaughnessy JOC, Osborne C, Pippen JE et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364, 205-214 (2011
-
(2011)
N. Engl. J. Med.
, vol.364
, pp. 205-214
-
-
O'Shaughnessy, J.O.C.1
Osborne, C.2
Pippen, J.E.3
-
149
-
-
80052330662
-
A randomized Phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC
-
O'Shaughnessy JOC, Schwartzberg LS, Danso MA et al. A randomized Phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J. Clin. Oncol. 29(Suppl.), 1007 (2011
-
(2011)
J. Clin. Oncol.
, vol.29
, Issue.SUPPL.
, pp. 1007
-
-
O'Shaughnessy, J.O.C.1
Schwartzberg, L.S.2
Danso, M.A.3
-
150
-
-
84862907868
-
Iniparib non-selectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor
-
Liu X, Shi Y, Magg DX, Palma JP, Patterson MJ. Iniparib non-selectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin. Cancer Res. 18(2), 510-523 (2012
-
(2012)
Clin. Cancer Res.
, vol.18
, Issue.2
, pp. 510-523
-
-
Liu, X.1
Shi, Y.2
Magg, D.X.3
Palma, J.P.4
Patterson, M.J.5
|